argenex SE (NASDAQ:ARGX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of argenex SE (NASDAQ:ARGX) have earned a consensus rating of “Moderate Buy” from the twenty-four brokerages that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $1,023.3889.

ARGX has been the topic of a number of recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Morgan Stanley raised their target price on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a report on Wednesday. Glj Research upgraded argenex to a “strong-buy” rating in a report on Friday, April 3rd. Robert W. Baird raised their target price on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Finally, Oppenheimer dropped their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd.

argenex Stock Performance

Shares of argenex stock opened at $888.65 on Friday. argenex has a 52 week low of $510.05 and a 52 week high of $934.62. The stock has a 50 day moving average price of $829.67 and a two-hundred day moving average price of $809.35. The stock has a market capitalization of $55.27 billion, a PE ratio of 39.57, a price-to-earnings-growth ratio of 1.30 and a beta of 0.47.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. Research analysts forecast that argenex will post 26.19 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Abound Wealth Management lifted its holdings in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC bought a new stake in argenex during the fourth quarter worth $28,000. Whipplewood Advisors LLC bought a new stake in argenex during the first quarter worth $28,000. Ameriflex Group Inc. bought a new stake in argenex during the third quarter worth $32,000. Finally, Sunbelt Securities Inc. bought a new stake in argenex during the third quarter worth $36,000. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.